The Recombinant Factor VIII Market continues to expand at a significant pace as global demand for advanced hemophilia A therapeutics rises steadily. Hemophilia A, an X-linked genetic disorder characterized by deficient clotting factor VIII, affects hundreds of thousands of patients worldwide and remains one of the most critical areas of unmet medical need in rare disease management. Recombinant...